Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)

A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) with pomalidomide through linkers of different lengths and types. The most promising degrader 17 possesse...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2021-07, Vol.64 (13), p.9120-9140
Hauptverfasser:	Xie, Shaowen, Sun, Yuan, Liu, Yulin, Li, Xinnan, Li, Xinuo, Zhong, Wenyi, Zhan, Feiyan, Zhu, Jingjie, Yao, Hong, Yang, Dong-Hua, Chen, Zhe-Sheng, Xu, Jinyi, Xu, Shengtao
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!